GleamWall
中文EN

NWBO NORTHWEST BIOTHERAPEUTICS INC

Pharmaceutical Preparations · OTC · SEC CIK 1072379 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY204.8%
TTM net income YoY55.8%
TTM EPS YoY50.0%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,608.8%
Net margin-1,388.8%
FCF margin-1,557.6%
EBITDA margin-1,517.8%

Returns

ROE—
ROA-74.3%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets160.8%
Debt / equity—
Current ratio0.03x
Interest coverage-4.89x

Cash quality & payout

Operating cash flow / net income1.09x
Accruals ratio6.6%
Payout ratio—
Capex / revenue45.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$883,000$807,000$494,000$672,000$200,000$131,000$375,000$231,000
R&D expense$4.22M$5.71M$4.86M$5.55M$7.45M$7.43M$8.35M$10.52M
SG&A expense$6.60M$6.71M$6.54M$8.62M$7.07M$7.48M$9.34M$8.21M
Operating income-$9.94M-$11.61M-$10.90M-$13.50M-$14.32M-$14.78M-$17.31M-$18.50M
Interest expense$2.60M$1.81M$2.35M$2.65M$2.62M$1.83M$1.60M$2.49M
Net income-$28.76M-$9.22M-$3.07M$1.39M-$26.83M-$15.38M-$19.34M-$28.22M
EBITDA-$9.34M-$11.11M-$10.13M-$12.78M-$13.92M-$14.28M-$16.88M-$18.05M
EPS (basic)-0.02-0.010.00—-0.02-0.01-0.01—
EPS (diluted)-0.02-0.010.00—-0.02-0.01-0.01—
Weighted avg. shares (diluted)1.71B1.64B1.58B—1.49B1.44B1.36B—
Balance sheet
Cash & equivalents$725,000$595,000$1.79M$3.04M$4.56M$4.32M$2.78M$2.17M
Current assets$2.43M$2.57M$6.20M$5.52M$7.20M$6.16M$4.69M$4.06M
PP&E, net$16.07M$16.48M$16.77M$17.41M$16.87M$16.68M$16.29M$16.20M
Goodwill$626,000$626,000$626,000$626,000$626,000$626,000$626,000$626,000
Intangibles$51.78M$51.93M$52.05M$53.19M———$1.29M
Total assets$76.14M$75.94M$80.05M$81.29M$30.61M$29.55M$27.50M$26.73M
Current liabilities$90.94M$73.35M$82.97M$91.70M$87.91M$83.92M$83.06M$68.27M
Long-term debt$64.51M$51.97M$59.43M$60.04M$72.20M$64.74M$64.14M$62.68M
Total debt$64.51M$51.97M$59.43M$60.04M$72.20M$64.74M$64.14M$62.68M
Total liabilities$122.44M$110.72M$118.11M$128.86M$125.86M$116.18M$112.34M$105.71M
Shareholders' equity-$56.70M-$45.17M-$50.54M-$60.28M-$108.65M-$100.39M-$99.48M-$94.49M
Net debt$63.79M$51.38M$57.64M$57.00M$67.64M$60.42M$61.37M$60.50M
Shares outstanding1.76B1.67B1.61B1.56B1.52B1.46B1.39B1.33B
Cash flow statement
Operating cash flow-$8.76M-$7.17M-$12.51M-$14.76M-$13.89M-$6.69M-$9.42M-$20.18M
Capital expenditure$53,000$198,000$129,000$905,000$202,000$304,000$93,000$78,000
Free cash flow-$8.81M-$7.37M-$12.64M-$15.67M-$14.10M-$6.99M-$9.51M-$20.26M
Investing cash flow-$53,000-$198,000-$129,000-$905,000-$513,000-$304,000-$93,000-$78,000
Financing cash flow$8.63M$7.37M$9.21M$13.59M$11.56M$12.45M$11.73M$15.94M
Depreciation & amortization$600,000$500,000$771,000$728,000$400,000$500,000$434,000$444,000
Stock-based compensation$148,000$181,000$288,000$185,000$273,000$364,000$385,000$476,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.